Survey sound off

Article

We’re still hearing from you about our second annual Issues & Attitudes Survey, such as these comments from your pediatric colleague in Succasunna, NJ.

Click here to see the complete results of our 2014 second annual Issues & Attitudes Survey.

Recent Videos
cUTI Roundtable: Discussing and diagnosing these difficult infections
Willough Jenkins, MD
Discussing health care sustainability, climate change, and WHO's One Health goal | Image credit: Provided by Shreya Doshi
Willough Jenkins, MD
Screening for and treating the metatarsus adductus foot deformity | Image Credit: UNFO md ltd
Wendy Ripple, MD
Wendy Ripple, MD
Courtney Nelson, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.
Related Content
Weekly review: Deli meats linked to listeria outbreak, roflumilast foam 0.3% sNDA submission and more

Weekly review: Deli meats linked to listeria outbreak, roflumilast foam 0.3% sNDA submission and more

Joshua Fitch, Senior Editor
July 26th 2024
Article

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome | Image Credit: © wladimir1804 - © wladimir1804 - stock.adobe.com.

FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome

Celeste Krewson, Assistant Editor
July 25th 2024
Article

ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA expands maralixibat label to include PFIC patients aged 12 months and older | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA expands maralixibat label to include PFIC patients aged 12 months and older

Joshua Fitch, Senior Editor
July 25th 2024
Article

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

Air pollution exposure during pregnancy linked to reduced lung function in childhood | Image Credit: © osnuya - © osnuya - stock.adobe.com.

Air pollution exposure during pregnancy linked to reduced lung function in childhood

Tim Smith
July 25th 2024
Article

These data highlighted the association of moderate air pollution exposure during pregnancy, infancy, and early childhood on pulmonary function at school age.

© 2024 MJH Life Sciences

All rights reserved.